Vaccinex Ownership
| VCNX Stock | USD 3.60 0.11 2.96% |
Shares in Circulation | First Issued 2017-03-31 | Previous Quarter 1.8 M | Current Value 2 M | Avarage Shares Outstanding 294.7 K | Quarterly Volatility 510.5 K |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Vaccinex |
Vaccinex Stock Ownership Analysis
About 49.0% of the company outstanding shares are owned by institutional investors. The company recorded earning per share (EPS) of 7.42. Vaccinex had not issued any dividends in recent years. The entity had 1:14 split on the 20th of February 2024. Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D . Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York. Vaccinex operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. For more information please call Maurice Zauderer at 585 271 2700 or visit https://www.vaccinex.com.Besides selling stocks to institutional investors, Vaccinex also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Vaccinex's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Vaccinex's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Vaccinex Quarterly Liabilities And Stockholders Equity |
|
Vaccinex Insider Trades History
About 9.0% of Vaccinex are currently held by insiders. Unlike Vaccinex's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Vaccinex's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Vaccinex's insider trades
Vaccinex Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vaccinex is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vaccinex backward and forwards among themselves. Vaccinex's institutional investor refers to the entity that pools money to purchase Vaccinex's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-06-30 | 0.0 | Tacita Capital Inc. | 2024-06-30 | 0.0 | Point72 Asset Management, L.p. | 2024-06-30 | 116.5 K | Armistice Capital, Llc | 2024-06-30 | 94 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.2 K | Tower Research Capital Llc | 2024-06-30 | 1.3 K | Group One Trading, Lp | 2024-06-30 | 67.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 53.0 | Royal Bank Of Canada | 2024-06-30 | 39.0 | Bank Of America Corp | 2024-06-30 | 8.0 | Capital Advisors, Ltd. Llc | 2024-09-30 | 3.0 |
Vaccinex Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaccinex insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaccinex's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vaccinex insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vaccinex Outstanding Bonds
Vaccinex issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vaccinex uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vaccinex bonds can be classified according to their maturity, which is the date when Vaccinex has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Vaccinex Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 25th of October 2024 Other Reports | ViewVerify | |
| 16th of October 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaccinex Stock Analysis
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.